Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Fuera de horario:
Shuttle Pharmaceuticals Holdings, Inc.
401 Professional Drive
Suite 260
Gaithersburg, MD 20879
United States
(240) 403-4212
https://www.shuttlepharma.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 8
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Anatoly Dritschilo M.D. | Co-Founder, CEO & Chairman of the Board | 399.18k | N/D | 1944 |
| Mr. Peter Dale Dritschilo M.B.A., M.D. | President & COO | 314.01k | N/D | 1969 |
| Dr. Milton Brown CSC, M.D., Ph.D. | Co-Founder & Director | N/D | N/D | 1965 |
| Mr. Michael P. Vander Hoek | CFO and VP of Operations & Regulatory | 302.53k | N/D | 1960 |
| Dr. Tyvin A. Rich M.D. | Chief Clinical Officer & Chief Medical Officer | 263.23k | N/D | 1948 |
| Dr. Mira Jung Ph.D. | Co-Founder & Chief Scientific Officer for Biology | N/D | N/D | 1949 |
| Mr. Gene Jung Esq. | General Counsel | N/D | N/D | N/D |
Descripción
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland.
Gestión corporativa
La calificación ISS Governance QuickScore de Shuttle Pharmaceuticals Holdings, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
